16.70
Schlusskurs vom Vortag:
$16.51
Offen:
$16.88
24-Stunden-Volumen:
9,869
Relative Volume:
0.19
Marktkapitalisierung:
$326.78M
Einnahmen:
$54,000
Nettoeinkommen (Verlust:
$-210.26M
KGV:
-21.14
EPS:
-0.79
Netto-Cashflow:
$-159.01M
1W Leistung:
-5.10%
1M Leistung:
+32.14%
6M Leistung:
+93.16%
1J Leistung:
-28.22%
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Firmenname
Lyell Immunopharma Inc
Sektor
Branche
Telefon
650 695-0677
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Vergleichen Sie LYEL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
LYEL
Lyell Immunopharma Inc
|
17.01 | 317.18M | 54,000 | -210.26M | -159.01M | -0.79 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
406.76 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
472.17 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
551.62 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
809.47 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
331.09 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-30 | Herabstufung | BofA Securities | Buy → Underperform |
2024-06-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-11-11 | Herabstufung | Goldman | Buy → Neutral |
2022-10-17 | Eingeleitet | H.C. Wainwright | Buy |
2021-07-12 | Eingeleitet | BofA Securities | Buy |
2021-07-12 | Eingeleitet | Goldman | Buy |
2021-07-12 | Eingeleitet | JP Morgan | Overweight |
2021-07-12 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
Tick level data insight on Lyell Immunopharma Inc. volatilityPortfolio Value Report & Free Safe Entry Trade Signal Reports - newser.com
Is it too late to sell Lyell Immunopharma Inc.Market Trend Review & Expert-Curated Trade Recommendations - newser.com
How to track smart money flows in Lyell Immunopharma Inc.Portfolio Gains Report & Consistent Income Trade Ideas - newser.com
Is Lyell Immunopharma Inc. showing signs of accumulationMarket Movement Recap & Expert Curated Trade Setup Alerts - newser.com
Is Lyell Immunopharma Inc. forming a reversal pattern2025 Market WrapUp & Long-Term Capital Growth Strategies - newser.com
Lyell Immunopharma (NASDAQ:LYEL) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Will Lyell Immunopharma Inc. continue its uptrend2025 Market Outlook & Risk Managed Investment Signals - newser.com
Clarius Group LLC Reduces Stake in Lyell Immunopharma, Inc. $LYEL - MarketBeat
Can trapped investors hope for a rebound in Lyell Immunopharma Inc.Long Setup & Technical Pattern Alert System - newser.com
Johnson & Johnson Reduces Stock Holdings in Lyell Immunopharma, Inc. $LYEL - MarketBeat
Smart tools for monitoring Lyell Immunopharma Inc.’s price actionPortfolio Update Summary & Long-Term Safe Investment Plans - newser.com
News impact scoring models applied to Lyell Immunopharma Inc.July 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com
Technical analysis overview for Lyell Immunopharma Inc. stockGlobal Markets & High Conviction Trade Alerts - newser.com
Trend analysis for Lyell Immunopharma Inc. this weekProduct Launch & Free Community Supported Trade Ideas - newser.com
Applying chart zones and confluence areas to Lyell Immunopharma Inc.Earnings Overview Report & Capital Efficiency Focused Strategies - newser.com
Will Lyell Immunopharma Inc. stock deliver long term returns2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Using Ichimoku Cloud for Lyell Immunopharma Inc. technicals2025 Stock Rankings & Community Trade Idea Sharing Platform - newser.com
How moving averages guide Lyell Immunopharma Inc. tradingPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Voya Investment Management LLC Sells 2,606 Shares of Lyell Immunopharma, Inc. $LYEL - Defense World
Applying Elliott Wave Theory to Lyell Immunopharma Inc.Market Risk Analysis & Consistent Profit Trading Strategies - newser.com
Goldman Sachs Group Inc. Has $193,000 Position in Lyell Immunopharma, Inc. $LYEL - Defense World
What’s the recovery path for long term holders of Lyell Immunopharma Inc.Weekly Loss Report & Consistent Return Investment Signals - newser.com
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lyell Immunopharma Inc-Aktie (LYEL) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Hill Stephen J. | Chief Operating Officer |
Aug 21 '25 |
Sale |
10.54 |
1,004 |
10,586 |
15,845 |
Newton Charles W. | Chief Financial Officer |
Aug 21 '25 |
Sale |
10.54 |
1,453 |
15,320 |
15,306 |
Lee Gary K. | Chief Scientific Officer |
Aug 21 '25 |
Sale |
10.54 |
1,453 |
15,320 |
15,504 |
Seely Lynn | President and CEO |
Aug 12 '25 |
Sale |
10.34 |
406 |
4,197 |
34,828 |
Seely Lynn | President and CEO |
Aug 11 '25 |
Sale |
10.53 |
391 |
4,116 |
35,234 |
Hill Stephen J. | Chief Operating Officer |
Aug 12 '25 |
Sale |
10.34 |
94 |
972 |
8,849 |
Hill Stephen J. | Chief Operating Officer |
Aug 11 '25 |
Sale |
10.53 |
91 |
958 |
8,943 |
Lee Gary K. | Chief Scientific Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,957 |
Lee Gary K. | Chief Scientific Officer |
Aug 11 '25 |
Sale |
10.53 |
131 |
1,379 |
9,093 |
Newton Charles W. | Chief Financial Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,759 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):